|
|
Volumn 34, Issue 5, 2002, Pages 1903-1905
|
|
A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: 6-Month interim analysis
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
INTERLEUKIN 2 RECEPTOR ANTIBODY;
DACLIZUMAB;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENT;
MONOCLONAL ANTIBODY;
ADULT;
BIOACCUMULATION;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
FOLLOW UP;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
KIDNEY TRANSPLANTATION;
MAJOR CLINICAL STUDY;
MULTICENTER STUDY;
PANCREAS TRANSPLANTATION;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
ANTIBODY PRODUCTION;
ARTICLE;
COMPARATIVE STUDY;
DISEASE FREE SURVIVAL;
DRUG ADMINISTRATION;
DRUG COMBINATION;
FEMALE;
GRAFT REJECTION;
IMMUNOLOGY;
MALE;
METHODOLOGY;
POSTOPERATIVE COMPLICATION;
TIME;
ADULT;
ANTIBODIES, MONOCLONAL;
ANTIBODY FORMATION;
COMPARATIVE STUDY;
DISEASE-FREE SURVIVAL;
DRUG ADMINISTRATION SCHEDULE;
DRUG THERAPY, COMBINATION;
FEMALE;
FOLLOW-UP STUDIES;
GRAFT REJECTION;
HUMAN;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY TRANSPLANTATION;
MALE;
PANCREAS TRANSPLANTATION;
POSTOPERATIVE COMPLICATIONS;
TIME FACTORS;
HUMANS;
|
|
EID: 0035993808
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(02)03117-2 Document Type: Conference Paper |
|
Times cited : (11)
|
|
References (8)
|
